当代美国新生儿重症监护病房（NICUs）中预防性益生菌的使用：一项调查更新。
Contemporary use of prophylactic probiotics in NICUs in the United States: a survey update.
机构信息
Center for Perinatal Research, Nationwide Children's Hospital, Columbus, OH, USA.
Department of Pediatric Surgery, Nationwide Children's Hospital, Columbus, OH, USA.
出版信息
J Perinatol. 2024 May;44(5):739-744. doi: 10.1038/s41372-024-01952-0. Epub 2024 Mar 29.
OBJECTIVE
In 2015, 14.0% of US NICUs administered probiotics to very low birth weight infants. Current probiotic use prior to and after the Fall of 2023 (when FDA warnings were issued) remains unknown.
STUDY DESIGN
A survey was distributed to the American Academy of Pediatrics Section on Neonatal and Perinatal Medicine (August-November/2022) and Neonatology Solutions' Level III/IV NICUs (January-April/2023). Probiotic administration practices were investigated.
RESULTS
In total, 289 unique NICUs and 406 providers responded to the survey. Of those, 29.1% of NICUs administered prophylactic probiotics to premature neonates, however, this decreased considerably after FDA warnings were issued. Additionally, 71.4% of providers stated willingness to administer probiotics to premature infants if there was an FDA-approved formulation.
CONCLUSIONS
Probiotic use in US NICUs increased between 2015 and the Fall of 2023 and then dropped dramatically following warning letters from the FDA. The introduction of an FDA-approved probiotic may further expand administration.
目的
2015 年，美国有 14.0%的新生儿重症监护病房（NICU）为极低出生体重儿使用益生菌。目前尚不清楚 2023 年秋季（美国食品和药物管理局发布警告时）之前和之后的益生菌使用情况。
研究设计
本研究于 2022 年 8 月至 11 月向儿科学会新生儿和围产期医学分会（AAP SOP）和新生儿医学解决方案的 3 级/4 级 NICU （Neonatology Solutions）（2023 年 1 月至 4 月）分发了一份调查。调查了益生菌的使用情况。
结果
共有 289 家 NICU 和 406 名医护人员对该调查做出了回应。其中，29.1%的 NICU 为早产儿预防性使用益生菌，但在美国食品和药物管理局（FDA）发布警告后，这一比例大幅下降。此外，71.4%的医护人员表示，如果有经 FDA 批准的配方，他们愿意为早产儿使用益生菌。
结论
2015 年至 2023 年秋季期间，美国 NICU 中益生菌的使用有所增加，随后在美国食品和药物管理局（FDA）发出警告信后大幅下降。如果有一种经 FDA 批准的益生菌，其使用可能会进一步扩大。
Zotero 插件